Pharmaceutical Executive, Aug 1, 2008 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Aug 1, 2008
Features
Inside the Doughnut Hole
By Mason Tenaglia , Lauri Mitchell , Keith Mandia
An answer to your question: What does the Part D coverage gap do to drug sales?
Harbingers of Change
By IMS Health
The industry is a-changing. Here are eight seminal events that describe how.
Do Something!
By William Schiemann
Seven steps you never knew that could fix the sales force
Hard of (Ad)hering
By George Koroneos, Online Content & News Editor
Companies have responded to declining profits with a proliferation of patient compliance programs. But where is pharma in this paradigm shift?
Columns
Spanning the Treatment Gap
By Gayle Lorenzi , Barbara Schreiner , Jimmy Black
How a diabetes field team helped docs overcome the treatment gap
All Aboard!
By Marjorie Martin
Bring customers back into the conversation
Next Generation Event Consolidations
By Carol Krugman
The path from chaos to compliance is consolidation
Washington Report
Can Sentinel Save Drug Development?
By Jill Wechsler
FDA's new sentinel system shows the pendulum swing toward safety won't swing back anytime soon
Back Page
Salute to the Murines
By Patrick Clinton
There's a cure for everything, as long as the patient is a mouse
Global Report
Jumping the Gun
By Sarah Houlton
Britain's new approach to drug pricing isn't as bad as the industry feared.
Technology
Search for: Meaning
By J. Brooker Aker
Here's how to search for meaning through unstructured data.
From the Editor
Cutter's Way
By Patrick Clinton
FDA preemption is a hot issue for pharma, and it's likely to get hotter. But it's the wrong issue.

ADVERTISEMENT

Click here